Nes-Ziona, Israel — August 14, 2025 — Leads & Copy — Enlivex Therapeutics Ltd. (Nasdaq: ENLV) will host a webinar on Monday, August 18, 2025, at 8:00 AM Eastern Time to present and discuss 3-month topline results from the Phase IIa stage of its Phase I/IIa ENX-CL-05-001 trial, a double-blind, randomized, placebo-controlled multi-centered study evaluating Allocetra™ in patients with moderate to severe knee osteoarthritis.
The webinar will feature a detailed analysis of 3-month topline data from the Phase IIa stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II trial.
Osteoarthritis affects more than 32.5 million Americans and more than 300 million people worldwide.
The first stage of the trial, a Phase I open-label dose-escalation study, was completed to evaluate safety and tolerability and to determine optimal dosing.
The ongoing Phase IIa stage is a double-blind, randomized, placebo-controlled trial, assessing both safety and efficacy, with endpoints measuring joint pain and function versus placebo at 3, 6, and 12 months post-injection. To date, 134 patients have completed the 3-month follow-up period.
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions.
ENLIVEX CONTACT:
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com
INVESTOR RELATIONS CONTACT:
Dave Gentry, CEO
RedChip Companies Inc.
1-407-644-4256
ENLV@redchip.com
Register for the webinar: https://www.redchip.com/webinar/ENLV/87053863717
Source: Enlivex Therapeutics Ltd.
